Literature DB >> 7489405

Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions.

D Weinstat-Saslow1, M J Merino, R E Manrow, J A Lawrence, R F Bluth, K D Wittenbel, J F Simpson, D L Page, P S Steeg.   

Abstract

The elucidation of molecular alterations that occur during human breast cancer progression may contribute to the development of preventative strategies. Using in situ hybridizations on a cohort of 94 biopsy lesions, quantitatively increased cyclin D mRNA expression levels were observed in only 18% of benign lesions, which confer no or slightly increased breast cancer risk, and 18% of premalignant atypical ductal hyperplasias, which confer a four to fivefold increase in breast cancer risk. The transition to carcinoma was accompanied by frequent cyclin D mRNA overexpression in 76% of low-grade ductal carcinomas in situ, 87% of higher grade comedo ductal carcinomas in situ and 83% of infiltrating ductal breast carcinomas. The data identify a molecular event that may separate benign and premalignant human breast lesions from any form of breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489405     DOI: 10.1038/nm1295-1257

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  81 in total

Review 1.  Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.

Authors:  R J Michalides
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

2.  The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition.

Authors:  S D Westerheide; M W Mayo; V Anest; J L Hanson; A S Baldwin
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 3.  A specific role for cyclin D1 in mammary gland development.

Authors:  P Sicinski; R A Weinberg
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-10       Impact factor: 2.673

4.  Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.

Authors:  E Neuman; M H Ladha; N Lin; T M Upton; S J Miller; J DiRenzo; R G Pestell; P W Hinds; S F Dowdy; M Brown; M E Ewen
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

5.  Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome.

Authors:  Vandana Gupta Abramson; Andrea B Troxel; Michael Feldman; Carolyn Mies; Yan Wang; Lauren Sherman; Sara McNally; Alan Diehl; Angela Demichele
Journal:  Anticancer Res       Date:  2010-04       Impact factor: 2.480

Review 6.  Imaging oncogene expression.

Authors:  Archana Mukherjee; Eric Wickstrom; Mathew L Thakur
Journal:  Eur J Radiol       Date:  2009-03-04       Impact factor: 3.528

7.  Competitive nuclear export of cyclin D1 and Hic-5 regulates anchorage dependence of cell growth and survival.

Authors:  Kazunori Mori; Etsuko Hirao; Yosuke Toya; Yukiko Oshima; Fumihiro Ishikawa; Kiyoshi Nose; Motoko Shibanuma
Journal:  Mol Biol Cell       Date:  2008-10-22       Impact factor: 4.138

Review 8.  Cyclins and breast cancer.

Authors:  Robert L Sutherland; Elizabeth A Musgrove
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

Review 9.  Cyclin D1 and human neoplasia.

Authors:  R Donnellan; R Chetty
Journal:  Mol Pathol       Date:  1998-02

10.  Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide.

Authors:  Clement G Yedjou; Paul B Tchounwou
Journal:  Mol Cell Biochem       Date:  2009-05-15       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.